News Related to Zovegalisib

Related coverage linked through entity extraction aliases.

Relay Therapeutics Reports Revenue Growth, Narrower Loss, and FDA Breakthrough for Zovegalisib

Mar 03, 2026

Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.

MoonLake on Track for HS BLA Submission; Relay's Zovegalisib Receives FDA Breakthrough Status

Feb 24, 2026

MoonLake Immunotherapeutics says FDA feedback indicates sufficient data to support a U.S. BLA for hidradenitis suppurativa without additional efficacy trials, while Relay Therapeutics received FDA Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant breast cancer.